Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 26, 2021

EMA’s CHMP begins rolling review of molnupiravir to treat Covid-19 in adults

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of molnupiravir (MK-4482 and EIDD-2801), an investigational oral antiviral medicine, to treat adult patients with Covid-19.

EMA will assess the quality, safety and effectiveness data of molnupiravir. Credit: © 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.